SCHEMBL5859609

SCHEMBL5859609

CC(C)(C)[C@H]1CC[C@H](C(=O)Cl)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GLA P06280 1/20 0.44
HSD11B1 P28845 1/20 0.44
EPHX1 P07099 1/20 0.42
NPC1 O15118 1/20 0.40
LIPA P38571 1/20 0.40
RAB9A P51151 1/20 0.39
EPHX2 P34913 1/20 0.37
MAPT P10636 2/20 0.36
ALDH1A1 P00352 2/20 0.36
RECQL P46063 1/20 0.36
ATM Q13315 1/20 0.36
RXRA P19793 1/20 0.36
RXRB P28702 1/20 0.36
RXRG P48443 1/20 0.36
CYP2D6 P10635 1/20 0.35
KCNH2 Q12809 1/20 0.35
HRH3 Q9Y5N1 1/20 0.35
APOBEC3A P31941 1/20 0.34
APOBEC3G Q9HC16 1/20 0.34
KDM4E B2RXH2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2900059 1.00 GLA (0.44) GLAHSD11B1EPHX1NPC1LIPA
SCHEMBL5728882 1.00 GLA (0.44) GLAHSD11B1EPHX1NPC1LIPA
SCHEMBL27549896 0.80 GLA (0.47) GLAHSD11B1EPHX1NPC1LIPA
SCHEMBL1506461 0.79 CHRNB2 (0.36) MAPT
SCHEMBL1060400 0.79 CHRNB2 (0.36) MAPT
SCHEMBL890380 0.79 CHRNB2 (0.36) MAPT
SCHEMBL4279 0.79
SCHEMBL503482 0.78 GLA (0.50) GLAHSD11B1EPHX1NPC1LIPA
SCHEMBL1835036 0.78 GLA (0.46) GLAHSD11B1EPHX1NPC1LIPA
SCHEMBL1835961 0.78 GLA (0.50) GLAHSD11B1EPHX1NPC1LIPA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4317128-B1 TRISAMIDE COMPOUNDS AND COMPOSITIONS COMPRISING THE SAME MILLIKEN & CO (US) 2025-07-23 EP disclosed
US-12358864-B2 Trisamide compounds and compositions comprising the same MILLIKEN & COMPANY (US) 2025-07-15 US disclosed
CN-117756661-A Triamide compound and composition comprising same 美利肯公司 2024-03-26 CN disclosed
EP-4317128-A2 TRISAMIDE COMPOUNDS AND COMPOSITIONS COMPRISING THE SAME Milliken & Company (US) 2024-02-07 EP disclosed
EP-4073029-B1 TRISAMIDE COMPOUNDS AND COMPOSITIONS COMPRISING THE SAME MILLIKEN & CO (US) 2024-01-31 EP disclosed
CN-115066413-B Triamide compound and composition comprising same 美利肯公司 2024-01-09 CN disclosed
US-20230331660-A1 TRISAMIDE COMPOUNDS AND COMPOSITIONS COMPRISING THE SAME MILLIKEN & COMPANY 2023-10-19 US disclosed
US-11724983-B2 Trisamide compounds and compositions comprising the same MILLIKEN & COMPANY (US) 2023-08-15 US disclosed
EP-4073029-A1 TRISAMIDE COMPOUNDS AND COMPOSITIONS COMPRISING THE SAME Milliken & Company (US) 2022-10-19 EP disclosed
CN-109071458-B Triamide compounds and compositions comprising the same 美利肯公司 2021-12-10 CN disclosed
EP-3426639-A1 TRISAMIDE COMPOUNDS AND COMPOSITIONS COMPRISING THE SAME Milliken & Company (US) 2019-01-16 EP disclosed
US-20170260129-A1 TRISAMIDE COMPOUNDS AND COMPOSITIONS COMPRISING THE SAME MILLIKEN & CO (US) 2017-09-14 US disclosed
WO-2017156099-A1 TRISAMIDE COMPOUNDS AND COMPOSITIONS COMPRISING THE SAME MILLIKEN & COMPANY (US) 2017-09-14 WO disclosed
US-7074790-B2 5-ethylimidarotriazones BAYER HEALTHCARE AG (DE) 2006-07-11 US disclosed
US-20060040942-A1 5-ethylimidarotriazones BAYER HEALTHCARE AG (DE) 2006-02-23 US disclosed
US-20050272732-A1 5-ethyl-imidazo (5,1-F) (1,2,4,) triazin-4 (3h)-ones as phosphodiesterase inhibitors BAYER HEALTHCARE AG (DE) 2005-12-08 US disclosed
EP-1506198-A1 5-ETHYLIMIDAROTRIAZONES Bayer HealthCare AG (DE) 2005-02-16 EP disclosed
EP-1504006-A1 5-ETHYL-IMIDAZO[5,1-F][1,2,4]TRIAZIN-4(3H)-ONES AS PHOSPHODIESTERASE INHIBITORS Bayer Aktiengesellschaft (DE) 2005-02-09 EP disclosed
WO-2003097645-A1 5-ETHYLIMIDAROTRIAZONES BAYER HEALTHCARE AG (DE) 2003-11-27 WO disclosed
WO-2003093270-A1 5-ETHYL-IMIDAZO (5,1-F) (1,2,4,) TRIAZIN-4 (3H) -ONES AS PHOSPHODIESTERASE INHIBITORS BAYER HEALTHCARE AG (DE) 2003-11-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060040942-A1 5-ethylimidarotriazones IL5, EPX, NFATC1 GLA 3180/4885HSD11B1 2329/4885EPHX1 625/4885
US-11724983-B2 Trisamide compounds and compositions comprising the same PTAR1, TIPRL, TCOF1 GLA 612/4885HSD11B1 3105/4885EPHX1 3394/4885
US-20230331660-A1 TRISAMIDE COMPOUNDS AND COMPOSITIONS COMPRISING THE SAME PTAR1, TIPRL, TCOF1 GLA 612/4885HSD11B1 3105/4885EPHX1 3394/4885
US-12358864-B2 Trisamide compounds and compositions comprising the same PTAR1, TIPRL, TCOF1 GLA 612/4885HSD11B1 3105/4885EPHX1 3394/4885
US-20050272732-A1 5-ethyl-imidazo (5,1-F) (1,2,4,) triazin-4 (3h)-ones as phosphodiesterase inhibitors PDE3A, PDE5A, PDE3B GLA 1211/4885HSD11B1 614/4885EPHX1 196/4885
US-20170260129-A1 TRISAMIDE COMPOUNDS AND COMPOSITIONS COMPRISING THE SAME TELO2, TERT, H1-2 GLA 2538/4885HSD11B1 4237/4885EPHX1 3027/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.